logo
  

DreamWorks Loss Wider Than Estimates

DreamWorks Animation SKG Inc (DWA) on Tuesday reported fourth-quarter net loss of $263.2 million or $3.08 per share compared with a profit of $17.2 million or $0.20 per share last year.

Results for the latest quarter included film and other inventory write-offs of $155.5 million and employee termination costs of $43.4 million, the company said.

Revenues for the quarter were up 14.7% at $234.2 million compared with $204.3 million in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $3.01 per share on revenues of $246.2 million for the quarter. Analysts' estimates typically exclude special items.

"Although 2014 was a challenging year for our company, I am confident that our recent announcement to restructure our feature film business will enable us to deliver great films and better box office results, while improving the overall financial performance of our business," said CEO Jeffrey Katzenberg.

In January, DreamWorks said it would cut 500 jobs and only produce two movies a year as the film studio tries to improve the performance of its animation movie business.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT